200 related articles for article (PubMed ID: 2408630)
1. Relationship between circulating interferon and anti-interferon antibodies and impaired natural killer cell activity in systemic lupus erythematosus.
Sibbitt WL; Gibbs DL; Kenny C; Bankhurst AD; Searles RP; Ley KD
Arthritis Rheum; 1985 Jun; 28(6):624-9. PubMed ID: 2408630
[TBL] [Abstract][Full Text] [Related]
2. Abnormal interferon modulation of natural cytotoxicity in systemic lupus erythematosus. Relation to suppressive serum factors.
Sibbitt WL; Froelich CJ; Bankhurst AD
Arthritis Rheum; 1983 Dec; 26(12):1452-9. PubMed ID: 6651894
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha regulation of lymphocyte function in systemic lupus erythematosus.
Sibbitt WL; Froelich CJ; Bankhurst AD
Clin Immunol Immunopathol; 1984 Jul; 32(1):70-80. PubMed ID: 6733982
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.
Sibbitt WL; Mathews PM; Bankhurst AD
J Clin Invest; 1983 May; 71(5):1230-9. PubMed ID: 6853711
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of natural killer cell activity by serum from patients with systemic lupus erythematosus: roles of disease activity and serum interferon.
Ytterberg SR; Schnitzer TJ
Ann Rheum Dis; 1984 Jun; 43(3):457-61. PubMed ID: 6204601
[TBL] [Abstract][Full Text] [Related]
6. Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus.
Hervier B; Ribon M; Tarantino N; Mussard J; Breckler M; Vieillard V; Amoura Z; Steinle A; Klein R; Kötter I; Decker P
Front Immunol; 2021; 12():633658. PubMed ID: 34012432
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cell activity in Sjögren's syndrome and systemic lupus erythematosus: stimulation with interferons and interleukin-2 and correlation with immune complexes.
Struyf NJ; Snoeck HW; Bridts CH; De Clerck LS; Stevens WJ
Ann Rheum Dis; 1990 Sep; 49(9):690-3. PubMed ID: 1700674
[TBL] [Abstract][Full Text] [Related]
8. Interferon and natural killer cells in systemic lupus erythematosus.
Strannegård O; Hermodsson S; Westberg G
Clin Exp Immunol; 1982 Nov; 50(2):246-52. PubMed ID: 6185256
[TBL] [Abstract][Full Text] [Related]
9. Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis.
Neighbour PA; Grayzel AI; Miller AE
Clin Exp Immunol; 1982 Jul; 49(1):11-21. PubMed ID: 6181920
[TBL] [Abstract][Full Text] [Related]
10. Abnormal macrophages and NK cell cytotoxicity in human systemic lupus erythematosus and the role of interferon and serum factors.
Zippel D; Lackovic V; Kocisková D; Rovenský J; Borecký L; Stelzner A
Acta Virol; 1989 Sep; 33(5):447-53. PubMed ID: 2483602
[TBL] [Abstract][Full Text] [Related]
11. [Interferon-α mediating the functional damage of CD56
Zhao XG; Liu JQ; Huang HN; Lu ZM; Bai ZR; Li X; Qi JJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 55(6):975-981. PubMed ID: 38101777
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Type-I IFN subtype autoantibodies and activity in SLE serum and urine.
Harris BD; Kuruganti S; Deshpande A; Goepfert PA; Chatham WW; Walter MR
Lupus; 2020 Aug; 29(9):1095-1105. PubMed ID: 32611267
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells and interferon responses in patients with systemic lupus erythematosus.
Tsokos GC; Rook AH; Djeu JY; Balow JE
Clin Exp Immunol; 1982 Nov; 50(2):239-45. PubMed ID: 6817954
[TBL] [Abstract][Full Text] [Related]
14. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus.
Oke V; Gunnarsson I; Dorschner J; Eketjäll S; Zickert A; Niewold TB; Svenungsson E
Arthritis Res Ther; 2019 Apr; 21(1):107. PubMed ID: 31036046
[TBL] [Abstract][Full Text] [Related]
15. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.
Munroe ME; Lu R; Zhao YD; Fife DA; Robertson JM; Guthridge JM; Niewold TB; Tsokos GC; Keith MP; Harley JB; James JA
Ann Rheum Dis; 2016 Nov; 75(11):2014-2021. PubMed ID: 27088255
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness.
Segerberg F; Lundtoft C; Reid S; Hjorton K; Leonard D; Nordmark G; Carlsten M; Hagberg N
Front Immunol; 2019; 10():2164. PubMed ID: 31572377
[TBL] [Abstract][Full Text] [Related]
17. Anti-NKG2A autoantibodies in a patient with systemic lupus erythematosus.
Hagberg N; Theorell J; Eloranta ML; Pascal V; Bryceson YT; Rönnblom L
Rheumatology (Oxford); 2013 Oct; 52(10):1818-23. PubMed ID: 23825044
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic and functional analysis of natural killer cells in systemic lupus erythematosus patients.
Chiang BL; Chen YC; Wang CR; Lin YL; Chou CC; Hsieh KH
Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi; 1995; 36(5):357-63. PubMed ID: 8607362
[TBL] [Abstract][Full Text] [Related]
19. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus.
Schepis D; Gunnarsson I; Eloranta ML; Lampa J; Jacobson SH; Kärre K; Berg L
Immunology; 2009 Jan; 126(1):140-6. PubMed ID: 18564343
[TBL] [Abstract][Full Text] [Related]
20. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia.
Slavikova M; Schmeisser H; Kontsekova E; Mateicka F; Borecky L; Kontsek P
J Interferon Cytokine Res; 2003 Mar; 23(3):143-7. PubMed ID: 12716486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
